Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. Atara ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $1.19 per share versus the Zacks Consensus Estimate of a loss of $3.82. This compares to loss of $14 per share a year ago. These ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed last Friday at $6.90. See what stocks are ...

ATRA opened at $6.91 on Wednesday. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $23.44. The stock has a market cap of $39.80 million, a P/E ratio of -0.27 and a beta of ...

THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Friday reported a loss of $12.7 million in its fourth quarter. The Thousand Oaks, California ...